Medios AG has successfully reallocated 6.7% of its shares from Bencis Capital Partners to institutional investor Janus Henderson Group, reflecting a strategic move to enhance its growth in the specialty pharmaceuticals sector.
Information on the Target
Medios AG is a prominent provider of specialty pharmaceuticals in Europe, with operations extending across Germany, the Netherlands, Belgium, and Spain. The company is dedicated to advancing individualized medicine, ensuring access to the latest therapeutic innovations. By collaborating with pharmacies, specialist practices, and pharmaceutical firms, Medios plays a crucial role in enhancing patient care through customized treatment options.
As Germany's first publicly listed specialty pharmaceutical company, Medios AG (ISIN: DE000A1MMCC8) is traded on the regulated market of the Frankfurt Stock Exchange under the Prime Standard. Moreover, Medios is part of the SDAX selection index, highlighting its significant presence and performance in the market.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Germany
The specialty pharmaceuticals sector in Germany has shown robust growth, driven by an increasing demand for innovative therapies and personalized medicine. With a strong emph
Similar Deals
athagoras → DiaMed Beratungsgesellschaft für pharmazeutische Unternehmen mbH
2025
Fidelity Management & Research Company, Janus Henderson Investors, Blackstone Multi-Asset Investing → Tubulis
2025
Janus Henderson Group Plc
invested in
Medios AG
in 2025
in a Other deal